InveniAI® reports a multi-target drug discovery collaboration with Shionogi & Co.
The multi-year collaboration will combine InveniAI’s AI platform, AlphaMeld®, to research and validate targets with Shionogi’s expertise in developing and commercializing appropriate therapeutic modalities. Shionogi will synthesize drugs against targets proposed by InveniAI for certain strategic diseases of interest to Shionogi and be responsible for developing, manufacturing, and commercializing the candidates.